Argenx Se (ARGX) Profit After Tax (2016 - 2026)
Argenx Se's (ARGX) quarterly Profit After Tax came in at $482.0 million in Q2 2026, up 167.93% YoY from $179.9 million in Q2 2025, and up 27.51% on a QoQ basis from $378.0 million in Q1 2026.
Analysis
Argenx Se (ARGX) Profit After Tax (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has 11 years of Profit After Tax data on file, last reported at $482.0 million in Q2 2026.
- Quarterly Profit After Tax rose 167.93% year-over-year to $482.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.6 billion (up 180.91% YoY) and the FY2025 annual result came in at $1.3 billion, up 55.1% from the prior year.
- Profit After Tax rose to $482.0 million in Q2 2026, from $378.0 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $482.0 million in Q2 2026 to a low of -$244.1 million in Q1 2022.
- A 5-year average of $62.5 million and a median of -$28.1 million in 2022 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax plunged 503.82% — and 2025, when it soared 1299.09%.
- Tracing ARGX's Profit After Tax over 5 years: stood at -$41.2 million in 2022, then sank by 48.35% to -$61.2 million in 2023, then soared by 237.06% to $83.9 million in 2024, then soared by 380.97% to $403.3 million in 2025, then advanced by 19.52% to $482.0 million in 2026.
- The last three Profit After Tax figures came in at $482.0 million (Q2 2026), $378.0 million (Q1 2026), and $403.3 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 585.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 472.00 Mn |
| Mar 31, 2026 | 366.00 Mn |
| Dec 31, 2025 | 532.95 Mn |
| Sep 30, 2025 | 344.26 Mn |
| Jun 30, 2025 | 245.36 Mn |
| Mar 31, 2025 | 169.00 Mn |
| Dec 31, 2024 | 774.16 Mn |
| Sep 30, 2024 | 91.41 Mn |
| Jun 30, 2024 | 29.07 Mn |
| Mar 31, 2024 | -61.60 Mn |
| Dec 31, 2023 | -99.17 Mn |
| Sep 30, 2023 | -72.64 Mn |
| Jun 30, 2023 | -94.37 Mn |
| Mar 31, 2023 | -28.87 Mn |
| Dec 31, 2022 | -38.61 Mn |
| Sep 30, 2022 | -235.04 Mn |
| Jun 30, 2022 | -208.75 Mn |
| Mar 31, 2022 | -227.19 Mn |
| Dec 31, 2021 | -237.82 Mn |
| Sep 30, 2021 | -233.61 Mn |